Skip to main content

Search form

Search

Medicines for Malaria Venture

Developing antimalarials to save lives

Research & Development
Access
Partnering
Our impact
About us
Malaria & medicines
Newsroom
MMV Open

Home
Newsroom
Press releases

Press releases

Filter

All

R&D

Access & product management

157 found

Single-dose Kozenis (tafenoquine) approved for children with Plasmodium vivax malaria by Australian Therapeutic Goods Administration

Novartis and Medicines for Malaria Venture report positive results for Phase IIb study of novel ganaplacide/lumefantrine combination in children with malaria

New partnership launched to accelerate elimination of relapsing P. vivax malaria that poses a risk to an estimated 2.5 billion people worldwide

Pyronaridine-artesunate demonstrates high real-life safety, tolerability and effectiveness in the treatment of uncomplicated malaria in large multi-country study in Africa

This World Malaria Day MMV recognizes Swiss Malaria Group's commitment to defeating malaria

New report demonstrates how R&D partnerships serving neglected communities have developed dozens of life-saving innovations since 2010

GSK, MMV filing for Kozenis (tafenoquine) in paediatric populations with Plasmodium vivax malaria accepted by Australian Therapeutic Goods Administration

MMV supports the launch of the new Fight the Fakes Alliance

Largest clinical trial in Africa to treat COVID-19 cases before they become severe

GSK and MMV present positive data on treatment of Plasmodium vivax malaria

Endemic countries in South America meet to discuss new tools for malaria elimination

Global call to boost access to lifesaving malaria treatment for pregnant women in Africa

MMV launches the COVID Box to stimulate new drug research

This World Malaria Day MMV supports Swiss Malaria Group's call for urgent action

Thailand becomes first malaria-endemic country in Asia-Pacific to approve tafenoquine for radical cure of P. vivax malaria

MMV and LSTM collaborate to fill data gap on use of antimalarials during pregnancy

International research partnership and EDCTP to invest €44m in next-generation antimalarials to combat drug-resistant malaria in Africa

Laboratory image

Research for new drugs against neglected diseases and malaria in Brazil to receive funding boost totaling BRL 43.5 million

Country leaders pledge to boost malaria innovation and access to new and existing antimalarials

Brazil becomes first malaria-endemic country to approve single-dose tafenoquine (Kozenis) for radical cure of P. vivax malaria

Life-saving malaria project in Zambia to expand

PATH and MMV launch 5-year global initiative to support elimination of relapsing malaria

Photo: Anna Wang/MMV

Europe-Africa partnership spearheads development of next-generation antimalarial drug

MMV and DNDi make 400 compounds available to stimulate research into new drugs for pandemic diseases

Two positive phase III studies of tafenoquine for the radical cure of Plasmodium vivax malaria published in The New England Journal of Medicine

World Malaria Report highlights importance of country-led efforts to defeat malaria in highest burden countries

Kozenis (tafenoquine) approved by the Australian Therapeutic Goods Administration for the radical cure of P. vivax malaria

Severe malaria case fatality reduced by 96% in pilot project in Zambia led by Transaid, MMV and partners

US FDA approves Krintafel (tafenoquine) for the radical cure of P. vivax malaria

US FDA Advisory Committee endorses the effectiveness and safety of single-dose tafenoquine for the radical cure of P. vivax malaria

WHO provides first-ever approval for rectal artesunate product for severe malaria

GSK submits US regulatory application for single-dose tafenoquine for Plasmodium vivax malaria

KAF156 enters phase IIb combination studies

Cipla launches quality-assured Rectal Artesunate Suppositories for severe malaria in young children

Three MMV-supported antimalarials listed as essential medicines

MMV and GSK announce positive headline phase III results showing single-dose tafenoquine reduces risk of relapse in patients with Plasmodium vivax malaria

MMV and Zydus join forces to develop new antimalarial

UCT-H3D, MMV and international partners identify second potent antimalarial candidate

MMV and Novartis expand partnership

Netherlands-based consortium teams up with MMV in world-leading malaria translational research programme

MMV joins Swiss Malaria Group in Bern to commemorate World Malaria Day

Pyramax® granules (pyronaridine-artesunate) for children added to WHO list of prequalified medicines

children

MMV announces collaborative agreement with S Kant HEALTHCARE Ltd

Pyramax® Granules becomes first paediatric antimalarial to receive EMA Article 58 positive scientific opinion

MMV provides QIMR Berghofer AU$10 M for malaria drug development

GHIT invests $10.7 million in malaria, TB, leishmaniasis and dengue research

Prof. Djimde and students at WANECAM Molecular Biology Workshop MRC Gambia

New study details safety and efficacy of re-treatment with Pyramax®

New compound has the potential to treat malaria patients in a single dose

GHIT, Takeda and MMV progress first-in-class antimalarial DSM265 to patient trials in Peruvian Amazon

Merck Serono and MMV sign agreement to develop potential antimalarial therapy

Japanese global health fund announces new investment in promising compounds for antimalarial drug discovery

Independent Safety Monitoring Board assessment enables recruitment of 2-5 year olds into OZ439/PQP Phase IIb trial

MMV announces collaborations with Cipla and Strides

GSK and MMV announce start of Phase III programme of tafenoquine

Potential new antimalarial drug identified at the University of Dundee

Breakthrough Therapy designation for potential new anti-relapse medicine for malaria

Campaign launched to help eliminate malaria deaths

Australian first to advance malaria medicines

Japan launches bold effort to fight neglected diseases

Winners of malaria photo contest announced

Pages

1
2
3
next ›
last »

Follow us

Facebook
LinkedIn
Twitter
YouTube

Subscribe

Sign up to our monthly newsletter

Previous newsletters

Contact us

Tel: +41 22 555 03 00
- Message us
- Office directions

© MMV 2022

Website by Manta Ray Media

Glossary
Disclaimer
Privacy
Sitemap